Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant drop in short interest in August. As of August 14th, there was short interest totaling 16 shares, a drop of 99.8% from the July 30th total of 9,551 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 322,731 shares, the short-interest ratio is presently 0.0 days.

Oncotelic Therapeutics Price Performance

Shares of OTCMKTS:OTLC opened at $0.03 on Wednesday. Oncotelic Therapeutics has a one year low of $0.01 and a one year high of $0.11. The stock has a fifty day moving average of $0.04 and a 200-day moving average of $0.04. The company has a market capitalization of $14.84 million, a PE ratio of 0.06 and a beta of -0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.08 and a current ratio of 0.08.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.